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Abstract 
The effect of glycosylation on the intracellular transport of human intestinal actase-phlorizin hydrolase (LPH) was investigated by biosynthetic 
labeling of biopsy samples in the presence or absence of glycosidase inhibitors. In the presence of deoxynojirimycin (dNM) and deoxymannojirimycin 
(dMM), endo H sensitive LPH glycoforms of M, = 135,000 in both cases were produced (LPHm,,, and LPH d,,,M). The LPH glycoform generated in 
the presence of swainsonine had an apparent molecular mass of 141,000 (LPH,,,) and was partially sensitive to endo H. By contrast to unmodified 
mature LPH (LPH,, M, = 160,000), these glycofonns are either not 0-glycosylated (LPH,,, and LPH ,,MM) or partially 0-glycosylated (LPH,,,) 
indicating that processing of N-linked carbohydrates has direct effects on the 0-glycosylation of pro-LPH. Analysis of transport kinetics of the various 
glycoforms strongly suggested that carbohydrate modification does not affect the transport of pro-LPH from the cis-Golgi to the cell surface, but 
could be rate limiting at the level of the ER. 
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1. Introduction 
Lactase-phlorizin hydrolase (LPH, EC 3.2.1.23-62) is 
an intestinal brush border glycoprotein that is abundant 
in almost all mammals. LPH converts lactose, the main 
carbohydrate in mammalian milk, to its two monosac- 
charide components. Studies in a variety of systems have 
established that LPH is synthesized as a large single- 
chain precursor (pro-LPH) that undergoes proteolytic 
cleavage to the final brush border form (LPHd [l-5]. In 
human intestinal cells [2,4,5] as well as in the pig small 
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and LPH obtained in the presence of dMM; pro-LPH,,, and LPH,,, 
pro-LPH and LPH obtained in the presence of swainsonine; endo 
F/GF, endo-B-N-acetylglucosaminidase F/glycopeptidase F; endo H, 
endo+?-%acetylglucosaminidase H; IM, intracellular membranes; 
BBM, brush border membranes; SDS-PAGE, sodium-dodecyl sulfate- 
polyacrylamide gel electrophoresis. 
intestine [l] cleavage takes place in the Golgi after com- 
plex glycosylation of pro-LPH. The role of intracellular 
cleavage has been recently investigated by transfection of 
COS-1 cells with a full length LPH cDNA [6]. Here, it 
was shown that uncleaved forms of pro-LPH could be 
transported to the cell surface in COS-1 cells and that 
processing of the carbohydrate side chains is not re- 
quired for the expression of enzymatically active LPH. 
Biosynthetic labeling studies of pro-LPH at reduced tem- 
peratures have demonstrated that at least a proportion 
of pro-LPH acquires complex glycosylated oligosac- 
charides before cleavage takes place [5]. However, it is 
not clear whether other forms of pro-LPH, for example 
differently glycosylated and/or improperly glycosylated 
molecules, could also be cleaved intracelluiarly. More- 
over, the effects of carbohydrate modification on the 
intracellular transport and cleavage of pro-LPH have 
not been so far elucidated. This is particularly interesting 
in view of recent findings on the processing of LPH in 
several cases of adult hypolactasia [7,8] in which the 
intracellular transport and proteolytic cleavage of pro- 
LPH are substantially delayed. 
In this paper the role of glycosylation on the intracel- 
lular transport and cleavage of pro-LPH has been inves- 
tigated using a pulse-chase protocol of biopsy explants 
in the presence of inhibitors of glycosylation. 
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2. Experimental 
2. I. Biosynthetic labeling of biopsy specimens and ~mmunoprecipi~ations 
Human small intestinal mucosa (approximately 5-10 mg wet weight) 
were obtained from patients biopsied for diagnostic purposes. They 
appeared normal when examined by light microscopy and expressed 
normal levels of bush-border disa~ha~dase activities. Bios~thetic 
labeling was performed according to Naim et al. 141. In brief, the biopsy 
specimens were washed three times in methionine-free RPM1 1640 
medium containing 10% dialyzed fetal calf serum (FCS) (Gibco), placed 
on stainless-steel grids in organ culture dishes (Falcon) [9] and incu- 
bated for 2 h at 37’C in a CO, + O2 (5:95, v/v) incubator. Thereafter 
the tissue was labeled with 150 @i of trm-[3SS]methionine (ICN) for 
6 h. In some experiments labelings were performed in the presence of 
inhibitors of glycosidases, dNM, dMM and swainsonine (Boehringer- 
Mannheim). Here, 5 mM dNM, 5 mM dMM (5 mM) and 4 pg/ml 
swainsonine were used. The inhibitors were present in the pre&uba- 
tion and labeling media. After labeling, the specimens were washed 
three times in RPM1 1640 and homogenized at 4°C with a Teflon-glass 
homogenizer in 1 ml of 25 mM Tris-HCl @H 8.1), 50 mM NaCl, and 
a cocktail of protease inhibitors containing 1 mM PMSF, 1 pg pep- 
statin, 5 pg ieu~ptin, 17.4pg Nadine and 1 pg aprotonin (all from 
Sigma). Processing of the biopsy homogenates for ~unopr~ipitation 
with monoclonal anti-human LPH (HBB l/909134/74) [Z] and SDS- 
polyacrylamide gel electrophoresis were performed as described else- 
where [4]. 
2.2. Other procedures 
Preparation of brush border membrane vesicles (BBM) and intracel- 
lular membranes (IM) from labeled mucosa, ~munop~ipitations, 
endo-N-,&acetylglucosaminidase F/glycopeptidase F (endo FIGF) (EC 
3.2.2.18 and EC 3.5.1.52, Boe~nger-M~nhe~), endive-a~tyl~u- 
cosaminidase H (EC 3.2.1.96, B~h~nger-Mannheim) treatment were 
performed according to Naim et al. [4,10,11]. Treatment of immunopre- 
cipitates with O-glycanase (EC 3.2.1.97, Boehringer-Mannheim) was 
essentially as described in [12] with the following modification. Im- 
m~opr~ipitat~ proteins were etuted with 20 ~11% SDS and 100 mM 
DTT in 0.1 M Tris-HCl, pH 8.0, by boiling for 5 min. To the eluates, 
10 pg of bovine serum albumin as a carrier protein was added, and the 
mixture was precipitated in 3 ~01s. of&e-cold acetone for 20 hat -20°C. 
The proteins were recovered by centrifugation, dried at 3’7°C and 
treated or not treated with neuraminidase (EC 3.2.1.18, Boehringer- 
Mannheim) and O-glycanase as described previously [12]. One-diien- 
sional SDS-~lyac~l~ide gel electrophoresis was conducted in 5% or 
6% polyac~lamide slab gels containing 0.1% SDS according to 
Laemmli [13]. 
3. Results 
3. I. Inhibition of oiigosaccharide processing affects the 
ER to Golgi but not the Golgi to cell surface tru~~~rt 
of pro-LPH 
To investigate the effect of carbohydrate modification 
on the transport of pro-LPH to the cell surface inhibitors 
of carbohydrate processing were used in conjunction 
with biosynthetic labeling studies of biopsy specimens, 
subcellular fractionations, i~unoprecipitations, endo 
F/GE endo H treatments and SDS-PAGE. The effect of 
the glycosidase inhibitors was monitored by the appear- 
ance of modified and cleaved forms of LPH. Further- 
more, cleavage of human pro-LPH in the Golgi provided 
a simple way by which the transport-competence of mod- 
ified pro-LPH forms could be assessed. Here, the trans- 
port rates of pro-LPH from the ER to the Golgi in the 
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Fig. 1. Effect of deoxynoji~ycin (dNM) on the processing of LPH. 
Biopsy samples were labeled for 6 h with [3sS]methionine i  the presence 
(lanes 3-5) or absence (lanes 1 and 2) of 5 mM dNM and homogenized. 
Detergent extracts of the homogenates were immunoprecipitated with 
monoclonal anti-LPH antibodies. Part of the i~unopr~ipitat~ was 
treated with endo H (lane 4), endo F/GF (lanes 2 and 5) or untreated 
(lanes 1 and 3). The samples were analyzed by SDS-PAGE on 6% slab 
gels and fluorography. 
lated with the proportion of pro-LPH that has under- 
gone cleavage in the Golgi. 
3.1.1. Effect of deoxynojirimycin (dNM) 
Deoxynojirimycin is a glucose analogue that inhibits 
the removal of the glucose residues from N-linked oligo- 
saccharides chain, Glc, Man, GlcNAc,, by oc-glucosi- 
dases I and II (EC 3.2.1.20) of the endoplasmic reticulum 
[14]. Fig. 1 demonstrates that in the presence of dNM 
LPH is composed of two polypeptides of apparent mo- 
lecular weights 215,000 (denoted pro-LPH,,,) and 
135,000 (denoted LPH,,,) (lane 3). Therefore, the size 
of the cleaved LPN,,, varied substantially from that of 
its counterpart in the dNM-non-treated sample, the 
M, = 160,000 (denoted LPH,,,) (Fig. 1, lane 1). 
Pro-LPH,,, and LPH,,, showed similar sensitivities 
to endo H as well as to endo F/GE; and were converted 
to M, = 2~~000 and 1M, = 118,000, respectively, upon 
treatment with either enzyme (Fig. 1, lanes 4 and 5). 
Since endo H cleaves mannose-rich glycan chains, while 
endo FlGF cleaves mannose-rich as well as complex type 
N-linked oligosaccharides, we conclude that pro- 
LPH,,, (M, = 215,000) and LPH,,, (M, = 135,000) 
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Fig. 2. Effects of deoxymannojirimycin (dMM) and swainsonine on the 
processing of LPH. Biopsy samples were labeled for 6 h with 
[35S]methionine i  the absence (lanes l-3) or presence of 5 mM dMM 
(lanes 46) or swainsonine (lanes 7-9) and homogenized. The detergent 
extracts of the homogenates were immunoprecipitated with monoclo- 
nal anti-LPH antibodies and subjected to analysis by SDS-PAGE on 
6% slab gels after treatment with endo H (lanes 2, 5, S), endo F/GF 
(lanes 3, 6, 9) or without treatment (lanes 1, 4, 7). Lanes 46 were run 
on the same gel as lanes l-3 and 7-9, but were taken from a longer 
exposed fluorogramme. 
carry predominantly mannose-rich oligosaccharides. 
The results indicate that the mannose-rich pro-LPHd,, 
has been transported to and cleaved in the Golgi where 
the putative protease is located. It is interesting to note 
the variations in the proportions of the cleaved LPH 
forms in the total LPH protein in dNM-treated and non- 
treated samples. Densitometric scannings of the fluoro- 
grams revealed that almost 46% of the total LPH protein 
in the dNM-treated biopsy sample was cleaved to 
LPHd,, within 6 h of labeling and 53% persisted as 
uncleaved pro-LPH,,, (Table 1) resulting in a ratio of 
0.87 of cleaved vs. uncleaved pro-LPH. In the control 
sample, on the other hand, 68% of total LPH protein was 
found in the cleaved form (LPH,, A& = 160,000) and 
3 1.5% as uncleaved pro-LPH (A4, = 2 15,000). The result- 
ing ratio of cleaved LPH, vs. uncleaved pro-LPH of 2.16 
is therefore 2.5-fold higher than that obtained in the 
presence of the inhibitor (Table 1). This indicates that 
within 6 h of biosynthetic labeling significantly less pro- 
LPHd,, molecules have been cleaved in the Golgi to 
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LPH,,, than in the absence of dNM (pro-LPH to 
LPH,,,). 
3.1.2. Effects of deoxymannojirimycin (dMM) and 
swainsonine (Swa) 
Deoxymannojirimycin inhibits the first steps in the 
processing of mannose-rich oligosaccharides by blocking 
the removal of four ol-1,Zlinked mannose-residues by 
the cis-Golgi a-mannosidase I (EC 3.2.1.113) [15]. 
Swainsonine blocks the removal of a-1,3 and a-l ,6 
linked mannoses by Golgi a-mannosidase II (EC 
3.2.1.114) [16]. In the presence of deoxymannojirimycin 
(dMM) the LPH band pattern revealed two polypep- 
tides, a mannose-rich precursor (denoted pro-LPH,,,, 
M, = 215,000) and a modified cleaved product of 
J4, = 135,000 (denoted LPH,,,) (Fig. 2, lane 4). Swain- 
sonine effect is manifested by the appearance of a modi- 
fied cleaved product of M, = 141,000 (denoted LPH,,,) 
(Fig. 2, lane 7). While LPH,,, was completely sensitive 
to endo H and converted to IV, = 118,000 (Fig. 2, lane 
5)> LPH,, showed partial sensitivity to the endoglyco- 
sidase (Fig. 2, lane 8). Both LPH,,,, and LPH,, re- 
vealed similar products of digestion upon treatment with 
endo F/GF (Fig. 2, lanes 6 and 9). The results indicated 
that the glycosylation pattern of LPH,,, contains 
mainly mannose-rich oligosaccharide chains. The partial 
sensitivity of LPH,, towards endo H is reminiscent of 
a hybrid type of glycosylation of this glycoform indicat- 
ing that at least partial trimming of mannose-rich pro- 
LPH,, has occurred. 
Scanning densitometry revealed that the cleaved prod- 
uct LPH,,, constituted 65% of the total synthesized and 
processed LPH, which is almost 2-fold that of pro- 
LPHd,, ( 32%) in dMM-treated cells (Table 1). The ratio 
of LPH,,, to pro-LPH,,, (2.03) is therefore similar to 
that in non-treated cells (2.16). An almost similar ratio 
was also obtained for LPH,, in total synthesized LPH 
protein. In this case, cleaved LPH,, constituted almost 
66% of the total LPH proteins which is similar to that 
found in the absence of the inhibitor (68%). 
3.1.3. Transport of LPH glycoforms from the Golgi to the 
brush border membrane 
Next the effect of glycosylation inhibitors on the trans- 
port of cleaved LPH to the cell surface was examined. 
Here, biopsy specimens were continuously labeled for 
Table 1 
Proportions of cleaved LPH in total synthesized LPH protein in the presence or absence of glycosidase inhibitors 
Glycosidase inhibitor LPH (M,) % in total LPH protein LPH LPH/pro-LPH (control) 
LPH Pro-LPH Pro-LPH LPH/pro-LPH (inhibitor) 
Not added 160,000 68 31.5 2.16 
dNM 135,000 46 53 0.87 2.5 
dMM 135,000 65 32.0 2.03 1.06 
Swainsonine 141,000 66 35 1.9 1.14 
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Fig. 3. Appearance of LPH glycoforms in the brush border membrane. 
Biopsy samples were labeled for 6 h with [“Slmethionine in the absence 
(lanes 1 and 3) or presence of 5 mM dMM (lanes 2 and 4) 6 PM 
swainsonine (Swa) (lanes 5 and 6) or 5 mM dNM (lanes 7 and 8) and 
homogenized. The homogenates were subcellularly fractionated into 
intracellular membranes (denoted IM) and brush border membranes 
(denoted BBM), solubilized, immunoprecipitated with anti-LPH anti- 
bodies and analyzed by SDS-PAGE on 6% slab gels. The figure is 
composed of three gels (lanes l-4) (lanes 5 and 6) (lanes 7 and 8). 
6 h in the presence or absence of dNM, dMM and swain- 
sonine. The biopsy homogenates were subcellularly frac- 
tionated to intracellular membranes (IM) and brush bor- 
der membranes (BBM) (see [4]). In the presence of dMM 
the modified cleaved LPH,,, form was revealed in the 
brush border membrane (BBM) fraction (Fig. 3, lane 4). 
Its proportion in total cleaved LPH (the sum of cleaved 
LPHd,, in the intracellular membranes (IM) (Fig. 3, 
lane 2) and brush border membrane (Fig. 3, lane 4)) was 
46% (Table 2). The LPH modified cleaved forms gener- 
ated in the presence of swainsonine (LPHs,, Fig. 3, lane 
6) and dNM (LPHdNM, Fig. 3, lane 8) were also trans- 
ported to the brush border membrane. Their proportions 
in total cleaved LPH were 42% (swainsonine) and 47% 
(dNM). In the absence of glycosidase inhibitors the pro- 
portion of the cleaved LPH molecule (LPH,, Fig. 3, lane 
3) in the brush border membrane was 46.5%. The results 
indicate that the proportion of cleaved LPH molecule 
that reach the cell surface is similar in all cases regardless 
of the presence or absence of inhibitors of glycosylation 
suggesting that the modification of the carbohydrate res- 
idues seems not to have affected the transport of cleaved 
LPH to the brush border membrane. 
3.2. 0-glycosylation of LPH is affected in the presence of 
glycosidase inhibitors 
Recently we have shown that the mature, brush border 
LPH molecule (LPH,, 160 kDa) is composed of at least 
two families of differently glycosylated molecules, an N- 
glycosylated LPH molecules (LPH,) and an N- and O- 
glycosylated (LPH& species [12]. Treatment of these 
two forms, i.e. the LPH, and LPH,,, with endo F/GF 
generates 118 kDa and 126 kDa polypeptides, respec- 
tively. In fact, as shown in the control biopsy sample 
(Fig. 2, lanes l-3) digestion of LPH, (lane 1) with endo 
F/GF (lane 3) produced two products: the O-glycosyl- 
ated 126 kDa species and the M, = 118,000, which corre- 
sponds to the N-deglycosylated form of LPH, (see [12]). 
Interestingly, the presence of the inhibitors dNM, dMM 
and swainsonine produced polypeptides that have only 
one product of deglycosylation with endo F/GF, which 
is represented by the M, = 118,000 (Fig. 1, lane 5; Fig. 
2, lanes 6 and 9) and is similar to the N-deglycosylation 
product of LPH,. This strongly suggests that O-glyco- 
sylation of LPH did not occur/or is at least affected in 
the presence of dNM, dMM, and swainsonine. To exam- 
ine this possibility, the different glycoforms of LPH, i.e. 
LPHd,,, LPH,,,, and LPHsw, were treated with neu- 
raminidaselo-glycanase to assess the presence or ab- 
sence of 0-glycosidically linked carbohydrates. The pres- 
ence of neuraminidase in the reaction is required if the 
substrate of 0-glycanase, Gal /I (l-3) GalNAc, is substi- 
tuted by sialic acid. Fig. 4 demonstrates that treatment 
of mature LPH, with neuraminidase/O-glycanase r - 
sulted in a reduction in its apparent molecular weight 
(lanes 1 and 2). It is important to note that previous data 
[12] have shown that LPH does not carry sialic acid 
residues supporting the notion that the observed shift in 
the apparent molecular weight of LPH (Fig. 4, lane 2) is 
due to the presence of 0-glycosidically-linked glycan 
units. By contrast, neuraminidaselo-glycanase did not 
affect the electrophoretic mobility of LPHd,, (lanes 3 
and 4) and LPH,,, (lanes 5 and 6) indicating that these 
forms do not contain O-linked carbohydrates. On the 
other hand, a slight alteration in the electrophoretic ap- 
pearance of LPH,,,,, from a diffuse band to a sharper 
polypeptide could be observed upon treatment with neu- 
raminidase/O-glycanase (Fig. 4, lanes 7 and 8). This sug- 
gests that LPH,,,,, has undergone some 0-glycosylation, 
but not as extensively as mature LPH,. The mannose- 
rich precursors of pro-LPH, on the other hand, were 
devoid of O-linked sugars regardless of the presence or 
Table 2 
Proportions of brush border LPH[LPH(BBM)] in total cleaved 
LPH[LPH(IM + BBM)]* in the presence or absence of glycosidase 
inhibitors** 
Glycosidase inhibitor LPH (M,) % LPH(BBM)/ 
LPH(IM + BBM) 
Not added 160,000 45.5 
dNM 135,000 47 
dMM 135,000 44.7 
Swainsonine 141,000 43.4 
*LPH(IM + BBM), total cleaved LPH that comprises LPH in the intra- 
cellular membranes (IM) and brush border membranes (BBM). 
**The results are representative of two experiments. 
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Fig. 4. Treatment of LPH glycoforms with neuraminidase/O-glycanase. 
Biopsy samples were labeled for 6 h with [?S]methionine in the absence 
(lanes 1 and 2) or presence of 5 mM dNM (lanes 3 and 4), 5 mM dMM 
(lanes 5 and 6) or 6 PM swainsonine (Swa) (lanes 7 and 8) homoge- 
nized, solubilized and immunoprecipitated with anti-LPH antibodies. 
Each immunoprecipitate was divided into two equal parts, one of which 
was treated with neuraminidase/O-glycanase (lanes 2,4, 6 and 8). The 
samples were analyzed by SDS-PAGE on 6% slab gels. The figure is 
composed of three gels (lanes 1 and 2) (lanes 3-6) (lanes 7 and 8). The 
shift in the apparent molecular weight of LPH (lane 2) is exclusively due 
to O-linked sugars and not due to neuraminidase treatment, since LPH 
does not carry sialic acids residues [12]. 
absence of glycosidase inhibitors, since no reactivity to- 
wards U-glycanase was observed (Fig. 4, lanes 1-8, 
upper bands indicated by the arrowheads). It should be 
noted that variations in the labeling intensities of the 
LPH glycoforms were observed after the incubations 
with or without neuraminidaselo-glycanase (Fig. 4, 
lanes 4, 6,7 and 8). This could be due to varying suscep- 
tibilities of the different LPH glycoforms to contaminat- 
ing proteases in the neuraminidase and O-glycanase 
preparations or due to spontaneous degradation during 
the long incubation procedure (24 h) at 37°C. 
4. Discussion 
The effect of glucosidase and mannosidase inhibitors 
on the transport and processing of pro-LPH could be 
clearly demonstrated by the appearance of cleaved LPH 
forms that varied in their glycosylation patterns. In the 
presence of dNM and dMM mannose-rich, endo H-sen- 
sitive cleaved LPH forms were detected, while in the 
presence of swainsonine a hybrid-type glycosylated, par- 
tially endo H sensitive LPH species was generated. These 
forms differ in their apparent molecular weights and in 
their endo H sensitivities from the cleaved LPH form 
(LPH,) obtained in the absence of the inhibitors. Except 
for deoxynojirimycin (dNM), the presence of the glyco- 
sidase inhibitors (dMM/swainsonine) in the tissue did 
not generate significant variations in the proportions of 
pro-LPH that have undergone intracellular cleavage. 
The notable exception was the significant reduction in 
the proportion of cleaved LPH (LPH,,,) observed upon 
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inhibition of the early trimming events of the glucose 
residues in the ER. One possible explanation of these 
results is that carbohydrate processing of the pro-LPH 
precursor in the ER, but not in the cis-Golgi, is impor- 
tant for pro-LPH to acquire a correct, transport-compe- 
tent conformation. Inhibition of carbohydrate process- 
ing by dNM, dMM and swainsonine did not have signif- 
icant influence on the trans-Golgi to cell surface trans- 
port, since comparable proportions of the cleaved gly- 
coforms were detected in the brush border membrane. In 
view of the observation that the only observed effect of 
carbohydrate processing is that in the presence of dNM, 
which functions in the ER, it is reasonable to assume that 
an effect of carbohydrate modification on the transport 
of LPH exists at the level of ER to Golgi transport. This 
in turn strongly supports the notion that the ER-Golgi 
transport constitutes the rate-limiting step along the se- 
cretory pathway of pro-LPH. 
Perhaps the most important finding of this study is 
that inhibition of the processing of N-linked carbohy- 
drates of pro-LPH has also inhibited or strongly inter- 
fered with 0-glycosylation of LPH. In fact, the gly- 
coforms generated in the presence of the inhibitors 
are either devoid of 0-glycosidically-linked oligosac- 
charides (LPHd,,, and LPH,,,) or are not as exten- 
sively 0-glycosylated (LPH,,,) as the fully processed and 
complex glycosylated LPH molecule (LPH,). It should 
be noted that dNM, dMM and swainsonine do not in- 
hibit the addition of 0-glycosidically-linked oligosac- 
charides per se. One possible explanation of this finding 
is that the inhibition of processing of N-linked carbohy- 
drates of pro-LPH has induced alterations in the protein 
folding of the pro-LPH molecule, which in turn render 
the molecule inaccessible to glycosyltransferases in- 
volved in O-linked glycosylation. These alterations ap- 
pear not to be directly involved in the transport of pro- 
LPH from the site of 0-glycosylation in the c&Golgi to 
the site of cleavage in the trans-Golgi, since in the pres- 
ence of dMM and swainsonine, whose site of action is 
the cis-Golgi, normal transport to the trans-Golgi and 
cell surface was obtained. Moreover, the proteolytic 
cleavage of pro-LPH to LPH was not affected indicating 
that these conformational alterations do not involve re- 
gions in the molecule implicated in this event. 
At present there is no uniform concept to understand 
the impact of carbohydrate processing of proteins on 
their intracellular transport. While in some cases efficient 
transport of secretory, membrane and lysosomal 
glycoproteins has been shown to be coupled to process- 
ing of their glycan units in the ER [17-231, several other 
investigations have demonstrated that these events are 
not rate-limiting of protein transport along the exocy- 
totic pathway [ 17,2427]. 
Our results have demonstrated that only inhibition of 
glucose trimming in the ER by dNM has significant 
effects on the intracellular transport of pro-LPH to the 
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cell surface. This suggests that a rate limiting step along 
the secretory pathway of pro-LPH and LPH does not 
exist in the Golgi. It is clear from all these examples that 
sugar modification in the ER and/or the Golgi induce 
alterations in the three dimensional structure or folding 
of proteins. Depending on the individual protein and the 
position of the N- and 0-glycosylation sites within the 
polypeptide backbone these alterations could take place 
near or in structures that are implicated in the intracellu- 
lar transport or perhaps in the function of the protein. 
Characterization of these regions may help unravel sev- 
eral aspects of the function and transport of these pro- 
teins. 
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